Table 1.

Inclusion Characteristics of Patients in Dupilumab Studies

Baseline Characteristics	Considerations
Failing > 500 µg of fluticasone propionate	Inclusion criterion for all of the phase 3 asthma trials
Failing an additional controller medication	Inclusion criterion for all of the phase 3 asthma trials
12% reversibility in FEV1 at baseline	Inclusion criterion for moderate-to-severe trials
Asthma Control Questionnaire > 1.5	Inclusion criterion for moderate-to-severe trials
Oral glucocorticoid dependent asthma	Inclusion criteria for severe steroid dependent trial

Abbreviation: FEV₁, forced expiratory volume in one second.